To aid in the identification and differentiation of Clostridium species, our specialized anaerobic culture optimized for Clostridium detects nearly 40 beneficial and pathogenic species, including C. botulinum, C. tetani and C. perfringens, as well as C. difficile, which is often present in healthy individuals, but can be associated with antibiotic-associated diarrhea. If C. difficile is cultured at any level, the sample is automatically tested for all known toxigenic strains using an FDA-cleared, molecular diagnostic DNA assay at no additional charge. [ LEARN MORE]
14 to 21 days
Note: Turnaround times on results are an estimate and are not guaranteed. The lab may need additional time due to holidays, confirmation/repeat testing, etc. You can contact us to discuss when your results should be ready.
Click any analyte name for additional clinical information, including reference ranges, specimen collection, stability and rejection criteria.
List price applies when filing with insurance or Medicare, or when billing a patient directly. Prompt payment pricing applies when billing to a physician account or prepayment is received with the test.
Doctor's Data offers profiles containing multiple analytes. *Multiple analytes may be billed under a single CPT code. Many analytes can be ordered individually. Pricing may vary. Click on a specific analyte for more information or read our detailed billing and payment policies.
The CPT codes listed on our website are for informational purposes only. This information is our interpretation of CPT coding requirements and may not necessarily be correct. You are advised to consult the CPT Coding Manual published by the American Medical Association. Doctor's Data, Inc. takes no responsibility for billing errors due to your use of any CPT information from our website.
Sign in at the top of any page to view pricing and order tests. Or click here to create an account. You may also contact us for assistance placing an order.
Clostridium is a diverse genus of bacteria, many of which are abundant and normal inhabitants of the human gastrointestinal tract (GIT). Many of the Clostridium species can have beneficial effects on the metabolism and health of the GIT in part by breakdown of polysaccharides, saccharolytic fermentation of carbohydrates to short chain fatty acids, and regulation of immune function. While non-pathogenic Clostridium species are predominantly saccharolytic, toxin-producing species tend to be strongly proteolytic. Proteolytic fermentation produces toxic metabolites such as ammonia, amines, volatile phenols and indoles which are pharmacologically active and affect a variety of physiological functionsâ€”including adverse effects in the central nervous system. Aside from the well-established pathogenic Clostridium species such as C. botulinum, C. tetani, C. perfringens and C. difficile, other species may have yet-to-be-elucidated roles in health and disease. For example, they may be involved as mediators in the gut-brain connection in the evolution of psychiatric neurodevelopmental delay such as autism and autism spectrum disorders. Clostridium species that produce neurotoxins and potentially toxic metabolic byproducts have been reported to be more prevalent in autistic children compared to neurotypical controlsâ€”most notable were greater quantities of C. bolteae and members of the C. hystolyticum group. Clostridia are anaerobic Gram-positive bacteria that do not grow in the more aerobic environment of the distal colon. However Clostridia produce extremely durable endospores as a means of proliferationâ€”the spores are resistant to air, antibiotics, heat, drying and disinfectants. Doctor's Data uses growth media optimally suited for growth of Clostridium species and anaerobic culture conditions to germinate the spores to metabolically active bacteria that are sub-cultured for positive identification (speciation). If C. difficile is cultured at any level, the sample is automatically tested for all known toxigenic strains using an FDA-cleared, molecular diagnostic DNA assay at no additional charge. Clostridia generally are resistant to antibiotics and treatment of an overgrowth of C. difficile, especially in asymptomatic carriers and infants under age two, is usually not warranted. Additionally, since plasmids have a potential role in transferring various capacities, including antibiotic resistance, from one organism to another, the use of antibiotics in the treatment of clostridia overgrowth should be considered carefully.